Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Document Type : Original Article

Authors

1 Department of Bacteriology, Immunology and Mycology Fac. Vet. Med. Benha University, Egypt

2 Department of diagnostic bacteriology. Veterinary serums and vaccines research Institute, Abbasia, Cairo, Egypt

3 Department of Biomedical Sciences & Pathobiology Virginia-Maryland College of Veterinary Medicine, USA

Abstract

Mycobacterium bovis BCG is attenuated strain derived from M. bovis. It has been known to prevent childhood pulmonary
and meningeal tuberculosis and to treat superficial bladder cancer as immunotherapy. Administration of BCG has been
restricted to immune-deficient individuals since 2007 because of its combined complications. Which treated with
antituberculosis drugs based on assumption is fully responsive to these drugs. BCG Connaught showed more
susceptibility to the activity of isoniazid, ethambutol, kanamycin, ofloxacin, streptomycin, amikacin and capreomycin
than BCG Pasteur growing in J774A.1 cells. While the activity of rifampicin and levofloxacin was the same between the
two tested strains. The spectrum of intracellular drug action can be ordered based on a decreasing order of inhibitory
activity, as following rifampin > isoniazid > ethambutol > streptomycin > kanamycin> amikacin> ofloxacin>
capreomycin> levofloxacin against BCG Connaught. While rifampin > isoniazid > ethambutol > kanamycin =
streptomycin > ofloxacin> amikacin> levofloxacin> capreomycin for BCG Pasteur. There is a very limited publications
describe the activity of antituberculosis drugs against intracellular growing BCG strains

Keywords

Benha Veterinary Medical Journal
Volume 31, Issue 1
September 2016
Pages 124-131

Files

Share

How to cite

Statistics